CD4 and Hodgkins lymphoma: This donor is representative of published findings on immune responses to those EBV latent antigens that are expressed in spontaneously arising tumors like Hodgkin's lymphoma and nasopharyngeal carcinoma; EBNA1 and LMP1 are mainly recognized by CD4+ T cells while LMP2 can be targeted by CD8+ T cells at least in HLA-A2 positive individuals with considerable frequency[7].